Leukemia Research
Volume 27, Issue 6 , Pages 547-555 , June 2003

Constitutively active mutant D816VKit induces megakayocyte and mast cell differentiation of early haemopoietic cells from murine foetal liver

  • Petranel T Ferrao

      Affiliations

    • School of Biomedical Sciences, Faculty of Health, University of Newcastle, Room 511, Medical Sciences Building, University Drive, Callaghan 2308, Australia
    • Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide 5000, Australia
    • ,
  • Thomas J Gonda

      Affiliations

    • Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide 5000, Australia
    • Present address: Bionomics Pty. Ltd, 31 Dalgleish Street, Thebarton 5031, SA, Australia.
    • ,
  • Leonie K Ashman

      Affiliations

    • School of Biomedical Sciences, Faculty of Health, University of Newcastle, Room 511, Medical Sciences Building, University Drive, Callaghan 2308, Australia
    • Hanson Centre for Cancer Research, Institute of Medical and Veterinary Science, Frome Road, Adelaide 5000, Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61-2-4921-7947; fax: +61-2-4921-6903.

Received 2 August 2002 ,Accepted 30 August 2002.

References 

  1. Galli SJ, Zsebo KM, Geissler EN. The Kit ligand, stem cell factor. Adv. Immunol. 1994;55:1–96
  2. Ashman LK. The biology of stem cell factor and its receptor c-Kit. Int. J. Biochem. Cell Biol. 1999;31:1037–1051
  3. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int. J. Biochem. Cell Biol. 1999;31:1053–1074
  4. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 1995;92:10560–10564
  5. Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J. Identification of activating c-Kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J. Invest. Dermatol. 1998;111:1227–1231
  6. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al.  Somatic c-Kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 1996;12:312–314
  7. Longley BJ, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al.  Activating and dominant inactivating c-Kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1609–1614
  8. Dror Y, Leaker M, Caruana G, Bernstein A, Freedman MH. Mastocytosis cells bearing a c-Kit activating point mutation are characterized by hypersensitivity to stem cell factor and increased apoptosis. Br. J. Haematol. 2000;108:729–736
  9. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, et al.  Detection of c-Kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 2000;53:188–193
  10. Jordan JH, Fritsche-Polanz R, Sperr WR, Mitterbauer G, Fodinger M, Schernthaner GH, et al.  A case of ‘smouldering’ mastocytosis with high mast cell burden, monoclonal myeloid cells, and c-Kit mutation Asp816Val. Leuk. Res. 2001;25:627–634
  11. Ashman LK, Ferrao P, Cole SR, Cambareri AC. Effects of mutant c-Kit in early myeloid cells. Leuk. Lymphoma. 2000;37:233–243
  12. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morra E, et al.  c-Kit mutations in core binding factor leukemias. Blood. 2000;95:726–727
  13. Ning ZQ, Li J, Arceci RJ. Activating mutations of c-Kit at codon 816 confer drug resistance in human leukemia cells. Leuk. Lymphoma. 2001;41:513–522
  14. Hongyo T, Li T, Syaifudin M, Baskar R, Ikeda H, Kanakura Y, et al.  Specific c-Kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan. Cancer Res. 2000;60:2345–2347
  15. Tian Q, Frierson HF, Krystal GW, Moskaluk CA. Activating c-kit gene mutations in human germ cell tumors. Am. J. Pathol. 1999;154:1643–1647
  16. Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-Kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer. 1998;83:2120–2129
  17. Sperr WR, Walchshofer S, Horny HP, Fodinger M, Simonitsch I, Fritsche-Polanz R, et al.  Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-Kit mutation Asp-816 to Val. Br. J. Haematol. 1998;103:740–749
  18. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-Kit and occurrence of the c-Kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 2000;28:140–147
  19. Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al.  Mutation analysis of c-Kit in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br. J. Haematol. 2001;113:357–364
  20. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-Kit product. J. Clin. Invest. 1993;92:1736–1744
  21. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al.  Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science. 1998;279:577–580
  22. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, et al.  Effect of c-Kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999;59:4297–4300
  23. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 1999;154:53–60
  24. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001;344:1052–1056
  25. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al.  Safety and efficacy of Imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421–1423
  26. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, et al.  The c-Kit mutation causing human mastocytosis is resistant to STI571 and other Kit kinase inhibitors kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood. 2002;99:1741–1744
  27. Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutanat V560GKit is more sensitive to Imatinib (STI571) compared to wild-type c-Kit whereas the kinase domain mutant D816VKit is resistant. Mol. Cancer Ther. 2002;1:1105–1114
  28. Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H, et al.  Constitutively activating mutations of c-Kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood. 1995;85:790–798
  29. Kitayama H, Tsujimura T, Matsumura I, Oritani K, Ikeda H, Ishikawa J, et al.  Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-Kit receptor tyrosine kinase. Blood. 1996;88:995–1004
  30. Piao X, Bernstein A. A point mutation in the catalytic domain of c-Kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood. 1996;87:3117–3123
  31. Ferrao P, Gonda TJ, Ashman LK. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood. 1997;90:4539–4552
  32. Tsujimura T, Furitsu T, Morimoto M, Kanayama Y, Nomura S, Matsuzawa Y, et al.  Substitution of an aspartic acid results in constitutive activation of c-Kit receptor tyrosine kinase in a rat tumor mast cell line RBL-2H3. Int. Arch. Allergy Immunol. 1995;106:377–385
  33. Hashimoto K, Tsujimura T, Moriyama Y, Yamatodani A, Kimura M, Tohya K, et al.  Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am. J. Pathol. 1996;148:189–200
  34. Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc. Natl. Acad. Sci. U.S.A. 1996;93:14665–14669
  35. Chian R, Young S, Danilkovitch-Miagkova A, Ronnstrand L, Leonard E, Ferrao P, et al.  Phosphatidylinositol-3-kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood. 2001;98:1365–1373
  36. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood. 2001;97:3559–3567
  37. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, et al.  Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6:3341–3351
  38. Aylett GCSR, Caruana, G, Ashman, LK. Specificity and functional effects of mAb to c-Kit protein (SCF receptor). In: Schlossman SFBL, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, et al., editors. Leukocyte typing V—white cell differentiation antigens. Oxford: Oxford University Press; 1995. p. 1917–20.
  39. Gonda TJ, Macmillan EM, Townsend PV, Hapel AJ. Differentiation state and responses to hematopoietic growth factors of murine myeloid cells transformed by Myb. Blood. 1993;82:2813–2822
  40. Ferrao P, Macmillan EM, Ashman LK, Gonda TJ. Enforced expression of full length c-Myb leads to density-dependent transformation of murine haemopoietic cells. Oncogene. 1995;11:1631–1638
  41. McNeil HP, Frenkel DP, Austen KF, Friend DS, Stevens RL. Translation and granule localization of mouse mast cell protease-5. Immunodetection with specific antipeptide Ig. J. Immunol. 1992;149:2466–2472
  42. Karnovsky MJ, Roots LA. A direct coloring tricholine method for cholinesterases. J Histochem Cytochem 1964;12:219–21.
  43. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am. J. Cytochem. Proc. 1971;55:283–290
  44. Lev S, Blechman J, Nishikawa S, Givol D, Yarden Y. Interspecies molecular chimeras of Kit help define the binding site of the stem cell factor. Mol. Cell. Biol. 1993;13:2224–2234
  45. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, et al.  Primary structure and functional expression of rat and human stem cell factor DNAs. Cell. 1990;63:203–211
  46. Moriyama Y, Tsujimura T, Hashimoto K, Morimoto M, Kitayama H, Matsuzawa Y, et al.  Role of aspartic acid 814 in the function and expression of c-Kit receptor tyrosine kinase. J. Biol. Chem. 1996;271:3347–3350
  47. Broudy VC. Stem cell factor and hematopoiesis. Blood. 1997;90:1345–1364
  48. Hu YL, Ramsay RG, Kanei-Ishii C, Ishii S, Gonda TJ. Transformation by carboxyl-deleted Myb reflects increased transactivating capacity and disruption of a negative regulatory domain. Oncogene. 1991;6:1549–1553
  49. McCormack MP, Gonda TJ. Expression of activated mutants of the human interleukin-3/interleukin-5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. Blood. 1997;90:1471–1481
  50. Briddell RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R. Effect of c-Kit ligand on in vitro human megakaryopoiesis. Blood. 1991;78:2854–2859
  51. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin 11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85:1719–1726
  52. Mayrhofer G, Gadd SJ, Spargo LD, Ashman LK. Specificity of a mouse monoclonal antibody raised against acute myeloid leukaemia cells for mast cells in human mucosal and connective tissues. Immunol. Cell. Biol. 1987;65:241–250
  53. Irani AM, Nilsson G, Miettinen U, Craig SS, Ashman LK, Ishizaka T, et al.  Recombinant human stem cell factor stimulates differentiation of mast cells from dispersed human fetal liver cells. Blood. 1992;80:3009–3021
  54. Valent P, Spanblochl E, Sperr WR, Sillaber C, Zsebo KM, Agis H, et al.  Induction of differentiation of mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/Kit ligand in long-term culture. Blood. 1992;80:2237–2245
  55. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21cip1. Mol. Cell. Biol. 1997;17:5598–5611
  56. Sewing A, Wiseman B, Lloyd AC, Land H. High-intensity Raf signal causes cell cycle arrest mediated by p21cip1. Mol. Cell. Biol. 1997;17:5588–5597
  57. Caruana G, Cambareri AC, Gonda TJ, Ashman LK. Transformation of NIH3T3 fibroblasts by the c-Kit receptor tyrosine kinase: effect of receptor density and ligand-requirement. Oncogene. 1998;16:179–190
  58. Tsujimura T, Hashimoto K, Kitayama H, Ikeda H, Sugahara H, Matsumura I, et al.  Activating mutation in the catalytic domain of c-Kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site. Blood. 1999;93:1319–1329
  59. Afonja O, Amorosi E, Ashman L, Takeshita K. Multilineage involvement and erythropoietin-“independent” erythroid progenitor cells in a patient with systemic mastocytosis. Ann. Hematol. 1998;77:183–186
  60. Cole SR, Aylett GW, Harvey NL, Cambareri AC, Ashman LK. Increased expression of c-Kit or its ligand steel factor is not a common feature of adult acute myeloid leukaemia. Leukemia. 1996;10:288–296
  61. Ruley HE. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature. 1983;304:602–606
  62. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596–602
  63. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature. 1999;400:464–468

PII: S0145-2126(02)00272-2

doi: 10.1016/S0145-2126(02)00272-2

Leukemia Research
Volume 27, Issue 6 , Pages 547-555 , June 2003

Article Tools

* Image Usage & Resolution